A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced
malignancies who have previously failed other therapies. The study has two phases. The
purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase
II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.